REG - Tristel PLC - Updated US guidelines for high level disinfection

TristelAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251124:nRSX6281Ia&default-theme=true

RNS Number : 6281I  Tristel PLC  24 November 2025

TRISTEL plc

("Tristel" or the "Company")

 

Updated US guidelines for high level disinfection

American Institute of Ultrasound in Medicine expands U.S. Guidelines to
include chlorine dioxide for high level disinfection of ultrasound probe

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
notes with satisfaction the publication by the American Institute of
Ultrasound in Medicine ("AIUM") regarding its expanded guidelines on the
handling and reprocessing of ultrasound probes in healthcare environments. For
the first time, the AIUM guidelines include chlorine dioxide as an accepted
option for high-level disinfection ("HLD").

 

Chlorine dioxide for ultrasound probe disinfection is branded as Tristel's HLD
foam product, Tristel ULT™, in the United States ("US"). Tristel ULT™ is
manufactured and distributed by Parker Laboratories under an exclusive
partnership agreement with Tristel, and is the only FDA-cleared chlorine
dioxide foam disinfectant for ultrasound probes available in the US market.

 

Matt Sassone, Chief Executive Officer of Tristel plc said: "We are delighted
to see AIUM's decision to include chlorine dioxide as an approved method for
high-level disinfection for ultrasound instruments. Together with the
inclusion last year of chlorine dioxide foam in the American national standard
on chemical sterilisation and high-level disinfection (ANSI/AAMI ST58:2024) -
which acknowledges this modality as a valid HLD option - this marks a
significant milestone for the U.S. market.

 

"Tristel ULT™ has been approved for use in more than 35 countries since 2008
and this update underscores the importance of our technology in highly
sterilised care environments where consistency and compliance are of critical
importance.

 

"With the AIUM guideline update and the enhanced national standard, we believe
the conditions are well-aligned for accelerated adoption of Tristel ULT™ in
the US ultrasound market - supporting frontline clinicians,
infection-prevention teams and hospital administrators alike."

 

For the full announcement on the revised guidelines from Tristel's partner,
Parker Laboratories, please see here
(https://www.morningstar.com/news/pr-newswire/20251119la28114/aium-expands-guidelines-to-include-chlorine-dioxide-for-high-level-disinfection-of-ultrasound-probes)
.

 

For further information please contact:

                                                                            Via Walbrook PR

 Tristel plc
 Matt Sassone, Chief Executive Officer                                      www.investors.tristel.com (https://investors.tristel.com/)
 Anna Wasyl, Chief Financial Officer

 Walbrook PR Ltd                                                            Tel: 020 7933 8780 or tristel@walbrookpr.com
 Paul McManus / Lianne Applegarth / Anna Dunphy    Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

 Cavendish Capital Markets Ltd                                              Tel: 020 7220 0500
 Geoff Nash / Callum Davidson / Trisyia Jamaludin (Corporate Finance)
 Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

 

 

About Tristel plc

 

Tristel plc is a global infection prevention company focussed on the
manufacture and supply of products using its unique proprietary chlorine
dioxide (ClO(2)) chemistry. The Company is a market leader in manual
decontamination of medical devices, supplying hospitals under the Tristel
(https://tristel.com/) brand, and under the Cache
(https://thecachecollection.com/) brand provides products for sporicidal
surface disinfection, a more sustainable alternative to commonly used
pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near
Cambridge, and operates globally employing approximately 270 people across 16
subsidiaries selling into 40+ countries. The Company targets double digit
revenue growth annually and an EBITDA margin of at least 25% and the business
is profitable, with no debt and has a progressive dividend policy.

 

The Company has been listed on the London Stock Exchange's AIM market since
2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit:
https://tristel.com (https://tristel.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBJBMTMTTTBLA



            Copyright 2019 Regulatory News Service, all rights reserved